News Releases

October 19, 2017

RepliCel Life Sciences Successfully Closes Financing
Shareholders commit to non-brokered private placement in clear support of the Company’s partnership strategy VANCOUVER, BC – October 19, 2017 – RepliCel Life Sciences... Read full article

September 13, 2017

RepliCel’s Partnership Initiatives Mature into Licensing Negotiations
Due diligence and confidential discussions now moving into negotiations for products in both the tendon repair and aesthetics franchises VANCOUVER, BC – September 13,... Read full article

September 7, 2017

RepliCel Showcases First Fully-Functional Prototypes of its Next-Generation Dermal Injector
Delivery of RepliCel’s patented prototypes kick-starts functional testing, matures licensing discussions, and confirms commercialization schedule VANCOUVER, BC – Sept. 07, 2017 – RepliCel Life... Read full article

August 16, 2017

RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program
Regenerative Medicine Company to Adopt ThawSTAR® Cell Thawing Systems to De-Risk Cell Therapy Clinical Trial VANCOUVER, British Columbia & SAN RAFAEL, Calif.–(BUSINESS WIRE)–MedCision, LLC,... Read full article

August 10, 2017

Prominent Skin Aging Researcher Provides Insights into RepliCel’s Clinical Data
“We believe that this novel therapy has the potential to rejuvenate skin in a way we’ve never seen before”, states key opinion leader in... Read full article

June 13, 2017

RepliCel Collaborates with University of British Columbia to Build World-Class Hair Follicle Cell Data Map
Data from this project expected to take RepliCel’s products to next level of potential commercial viability VANCOUVER, BC – June 13, 2017 – RepliCel... Read full article

May 25, 2017

RepliCel CEO Provides Company Outlook
A data-rich 2017 positions RepliCel for maturity through the next phase of its product development, research programs, and revenue generation VANCOUVER, BC – May... Read full article

April 25, 2017

United States Patent Issued to RepliCel for its Novel Dermal Injection Technologies
With exclusive U.S. rights to RCI-02 patents, RepliCel edges its nearest-term commercial asset closer to launch in large aesthetic market VANCOUVER, BC – April... Read full article

April 4, 2017

Positive Results from RepliCel’s RCS-01 Phase I Skin Trial are the Company’s Most Compelling to Date
Interim trial results lead researchers to conclude that the injection of RCS-01 is not only very safe, but also has the potential to reverse... Read full article

March 28, 2017

RepliCel’s Successful RCT-01 Tendon Repair Clinical Trial Shows Signs of Healing Chronic Tendon Problems
First-in-human clinical study meets primary endpoint demonstrating product safety and clinical potential for tendon regeneration and healing VANCOUVER, BC – March 28, 2017 –... Read full article